Table 2.

Status of the neutralizing antibodies in different phases in clinical trials.

Sl. No.	Name of nAb	Type of nAbs	Clinical trial No.	Status	Target site	Remarks
1.	JS016	Human mAb	NCT04441918	Phase I	Spike protein	Anti-SARS-CoV-2 monoclonal antibody targets spike protein and blocks binding of the virus to host cells
2.	TY027	Engineered human IgG	NCT04429529	Phase I completed/Phase III	SARS-CoV-2	Used for treatment of patients with COVID-19 to slow the progression of the disease and accelerate recovery, and providing temporary protection from infection
3.	BRII-196	Convalesced-derived human mAb	NCT04479631	Phase I	SARS-CoV-2	Non-overlapping epitope binding regions provide a high degree of neutralization activity against SARS-CoV-2.
4.	BRII-198	Convalesced-derived human mAb	NCT04479644	Phase I	SARS-CoV-2
5.	ABBV-47D11	Human mAb	NCT04644120	Phase I	Full-length spike protein (conserved region)	The cross-neutralizing antibody targets a shared epitope on viruses and could potential for prevention and treatment of COVID-19
6.	STI-1499	Cocktail mAb	NCT04454398	Phase I	Spike protein	Potent neutralizing activity against SARS-CoV-2 virus isolates, including the emerging spike D614G variant
7.	MW33	Humanized IgG1κ Ab	NCT04533048	Phase I	Receptor-binding domain	Recombinant fully human antibody applied for patients with mild or moderate COVID-19
8.	HFB30132A	Recombinant mAb	NCT04590430	Phase I	Spike protein	Fc modified IgG4 with minimized binding to the human FcγRs, which leads to decrease of risk for antibody-dependent enhancement of SARS-CoV-2 infection,
9.	ADM03820	Cocktail mAb	NCT04592549	Phase I	Spike protein	Mixture of two human IgG1 non-competitive binding anti-SARS-CoV-2 antibodies.
10.	HLX70	Human mAb	NCT04561076	Phase I	Receptor-binding domain	Genetically engineered, fully humanized mAb that targets RBD of SARS-CoV-2 for the treatment of COVID-19 and acute respiratory disorder
11.	DZIF-10c	Human mAb	NCT04631705	Phase I & Phase II	Receptor-binding domain	Intravenous infusion and by inhalation protection from virus infection in the respiratory tract.
12.	COVI-AMG	Hamster mAb	NCT04584697	Phase I & Phase II	Spike protein	The reduced activity and protected against the SARS-CoV-2 and the highly infectious spike (D614G) isolate.
13.	BGB DXP593	mAb cocktails	NCT04532294	Phase I	Spike ectodomain trimer	Overlaps with the RBD-ACE2 complex structure, and inhibiting the entrance of SARS-CoV-2
14.	SCTA01	Human mAb	NCT04483375	Phase I	Spike protein	Efficiently neutralized SARS-CoV pseudoviruses and SARS-CoV-2 by blocking the (RBD) S-protein
15.	CT-P59	Human mAb	NCT04525079	Phase I	Receptor-binding domain	Reduced the viral load in the upper and lower respiratory tracts and has therapeutic potential for patients with COVID-19.